# A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

> **NCT06239155** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ascentawits Pharmaceuticals, Ltd** · enrollment: 51 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** AST-3424

## Key facts

- **NCT ID:** NCT06239155
- **Lead sponsor:** Ascentawits Pharmaceuticals, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-03
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239155, "A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06239155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*